Central Nervous System Fungal Infections: Clinical Trials

61 trials for Central Nervous System Fungal Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 13 unknown, 8 recruiting, 2 terminated. 21 Not applicable, 13 Phase 2, 10 Phase 3, 6 Phase 4, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable21Completed 15, Unknown 5, Recruiting 1
Phase 213Completed 7, Recruiting 3, Terminated 2, Unknown 1
Phase 310Completed 3, Unknown 3, Recruiting 2, Not yet recruiting 1, Withdrawn 1
Phase 46Completed 4, Unknown 2
Phase 15Completed 5
Early Phase 11Unknown 1

Follow Central Nervous System Fungal Infections: new trials by email Literature Review of Central Nervous System Fungal Infections trials Research Report on Central Nervous System Fungal Infections

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers
Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole - Cryptococcal Antigenemia, HIV-1-infection
Phase 3Not yet recruitingUniversity of Minnesota5052027-01-052026-09-03
Olorofim in Early Coccidioidal Meningitis
olorofim - Coccidioidal Meningitis
Phase 2RecruitingFariba Donovan122026-06-012026-07-27
Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.
Biofire FilmArray Meningitis/Encephalitis Panel - Meningitis, Encephalitic Infection
Not applicableRecruitingFederal University of Health Science of Porto Alegre1822026-04-132026-08-21
Acute Treatment and Long-term Assessment of Adult Infectious Meningitis
Viral Meningitis, Bacterial Meningitis
RecruitingHospital Israelita Albert Einstein6242026-03-302026-08-13
Prospective Clinical Registry of Acute Treatment and Long-term Assessment of Children Meningitis
Meningitis, Bacterial Infections
RecruitingHospital Israelita Albert Einstein6002026-03-292026-05-05
Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)
Standard of care, Oteseconazole - antifungal therapy 1, Turletricin injection - antifungal therapy 2 - Hiv, Cryptococcal Meningitis
Phase 2 / Phase 3RecruitingDavid Boulware20002025-05-282026-07-27
Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
AMBITION trial control, Flucytosine - Cryptococcal Meningitis
Phase 2CompletedUniversity of Minnesota482024-04-092025-08-27
Amphotericin B for Non-HIV Cryptococcal Meningitis Patients
Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks., Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks. - Cryptococcal Meningitis, Antifungal Agents
Phase 4UnknownHuashan Hospital2502023-08-132023-12-21
Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City
Histoplasma Urine Antigen Lateral Flow Antigen test, Cryptococcal Lateral Flow Antigen test, Tuberculosis-lipoarabinomannan Lateral Flow Antigen test - Acquired Immunodeficiency Syndrome, Histoplasmosis AIDS
Not applicableUnknownNational Institute of Respiratory Diseases, Mexico2112023-04-012023-01-17
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
MAT2203, Amphotericin B - Cryptococcal Meningitis
Phase 3UnknownMatinas BioPharma Nanotechnologies, Inc.2702023-01-012022-09-15
Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis
Amphotericin B Colloidal Dispersion, flucytosine, fluconazole - Cryptococcal Meningitis
Not applicableUnknownPeking Union Medical College Hospital302022-08-222022-07-22
Early Diagnosis of Native and Device-associated Meningitis
D-lactate test, Standard diagnostic tests - Bacterial Meningitis, Fungal Meningitis
Not applicableUnknownCharite University, Berlin, Germany8422021-06-012021-12-07
Three Induction Treatments on Cryptococcal Meningitis
Voriconazole 200mg, amphotericin B deoxycholate (0.4-0.5mg/kg/d), Amphotericin B-deoxycholate (0.7-1.0mg/kg/d) - Cryptococcal Meningitis, HIV/AIDS
Early Phase 1UnknownFirst Affiliated Hospital of Zhejiang University1202021-01-252021-02-02
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week - Cryptococcal Meningitis
CompletedUniversity of Pharmacy, Yangon302020-10-012022-04-21
The Lived Experience of Participants in an African Randomised Trial
In-depth interviews - HIV, Cryptococcal Meningitis
CompletedLondon School of Hygiene and Tropical Medicine892020-02-052022-04-06
AmB Dose for Cryptococcal Meningitis
Amphotericin B, Flucytosine - Cryptococcal Meningitis, HIV Infections
Phase 3UnknownShanghai Public Health Clinical Center402020-01-022019-10-29
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
MAT2203, Amphotericin B - Cryptococcal Meningitis
Phase 1 / Phase 2CompletedMatinas BioPharma Nanotechnologies, Inc.1782019-10-242023-03-31
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
Single dose liposomal Amphotericin and Fluconazole, Fluconazole - Cryptococcal Meningitis
Phase 2 / Phase 3RecruitingMakerere University3562019-06-202026-04-28
Treatment With Tamoxifen in Cryptococcal Meningitis
Tamoxifen, Amphotericin B, Fluconazole - Meningitis Streptococcal, Hiv
Phase 2CompletedOxford University Clinical Research Unit, Vietnam502017-10-102019-12-02
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
DREAMM - AIDS-Related Opportunistic Infections, Meningo-encephalitis
Not applicableCompletedSt George's, University of London4952016-04-232022-05-04

Showing 20 of 61. Sign in to see all of them.

Narrower conditions

Meningitis, Cryptococcal (54)  ·  Acquired Immunodeficiency Syndrome (27)  ·  HIV Infections (25)  ·  Meningitis (24)  ·  Cryptococcosis (21)  ·  AIDS-Related Opportunistic Infections (17)  ·  Meningitis, Fungal (6)  ·  Meningitis, Bacterial (5)  ·  Meningitis, Viral (3)  ·  Bacterial Infections (2)  ·  Brain Diseases (2)  ·  Mycoses (2)  ·  Aspergillosis (1)  ·  Autoimmune Diseases (1)

Broader conditions

Bacterial Infections and Mycoses (61)  ·  Central Nervous System Diseases (61)  ·  Infections (61)  ·  Central Nervous System Infections (60)  ·  Nervous System Diseases (60)  ·  Mycoses (59)  ·  Neuroinflammatory Diseases (59)  ·  Meningitis, Fungal (53)  ·  Virus Diseases (38)  ·  Immune System Diseases (36)  ·  Blood-Borne Infections (35)  ·  Communicable Diseases (35)  ·  Immunologic Deficiency Syndromes (35)  ·  Lentivirus Infections (35)

Interventions

Fluconazole (28)  ·  Amphotericin B (23)  ·  Flucytosine (13)  ·  liposomal amphotericin B (4)  ·  amphotericin B, deoxycholate drug combination (3)  ·  Anidulafungin (2)  ·  Antiretroviral Therapy, Highly Active (2)  ·  Itraconazole (2)  ·  Lamivudine (2)  ·  Stavudine (2)  ·  Voriconazole (2)  ·  efungumab (2)  ·  Dexamethasone (1)  ·  Injections (1)  ·  Nevirapine (1)

Sponsors

Pfizer (12)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (8)  ·  University of Minnesota (5)  ·  National Hospital for Tropical Diseases, Hanoi, Vietnam (3)  ·  ANRS, Emerging Infectious Diseases (2)  ·  Hospital Israelita Albert Einstein (2)  ·  Matinas BioPharma Nanotechnologies, Inc. (2)  ·  Novartis Pharmaceuticals (2)  ·  University of Zimbabwe (2)  ·  Alkermes, Inc. (1)  ·  Botswana-UPenn Partnership (1)  ·  Charite University, Berlin, Germany (1)  ·  David Boulware (1)  ·  Fariba Donovan (1)  ·  Federal University of Health Science of Porto Alegre (1)

Countries

United States (25)  ·  Uganda (10)  ·  China (4)  ·  Vietnam (4)  ·  Zimbabwe (4)  ·  Brazil (3)  ·  Canada (3)  ·  South Africa (3)  ·  Thailand (3)  ·  Botswana (2)  ·  Cameroon (2)  ·  Peru (2)  ·  Burma (1)  ·  Burundi (1)  ·  Côte d’Ivoire (1)

Top investigators

Armstrong D (2)  ·  David R Boulware, MD, MPH (2)  ·  Radha Rajasingham, MD (2)  ·  Alessandro C Pasqualotto, PhD (1)  ·  Andrej Trampuz, PD Dr. med (1)  ·  Angela Loyse, MD (1)  ·  Anna M Gomes (1)  ·  Anna M Gomes, MD (1)  ·  Azure T Makadzange, MD DPhil (1)  ·  Azure T Makadzange, MD, DPhil (1)  ·  Charles Kouanfack, MD, PhD (1)  ·  Chiratidzo E Ndhlovu, MBBS, MSc (1)  ·  Chiratidzo E Ndhlovu, MBChB, FRCP (1)

Results publications

PMID 39972326, PMID 30325463, PMID 32843994, PMID 19441980, PMID 19897055, PMID 20415574, PMID 23362285, PMID 24963568, PMID 25376267, PMID 26050015, PMID 26768369, PMID 30256903, PMID 30345376, PMID 30399034, PMID 30801037, PMID 31242860, PMID 31319498, PMID 31345462, PMID 31504335, PMID 32634122, PMID 32747357, PMID 33677986, PMID 33820784, PMID 34398238, PMID 34446679, PMID 34581270, PMID 35924841, PMID 36303432, PMID 36780493, PMID 36924288, PMID 37133586, PMID 37606364, PMID 37802567, PMID 38152404, PMID 38943665, PMID 39044381, PMID 40665233, PMID 40795226

NIH funding

R01NS086312 (1), U01AI089244 (1), U01GH000517 (1)